TAT 2018 - Targeted Anticancer Therapies

Oncology Meeting Resources

05 Mar - 07 Mar 2018, Paris, France

TAT 2018

TAT 2018 - Targeted Anticancer Therapies focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents. Presentations and webcasts from the TAT 2018 - Targeted Anticancer Therapies are available here to ESMO members.

Watch ESMO video reports from experts:

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme  | Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...Targeting-histone-H3K36me3-deficient-cancers

SETD2-dependent histone H3 lysine 36 trimethylation (H3K36me3) plays a central role in both maintaining genome stability and in suppressing tumorigenesis, and is frequently depleted in particular cancer types.

Date: 05 Mar 2018
Presenter: Timothy Humphrey
Resources: Abstract, Presentation, Webcast
Topic: Anticancer Agents

https://oncologypro.esmo.org/Meeting-Resour...d-Anticancer-Therapies/BET-domain-inhibitors

Date: 05 Mar 2018
Presenter: Irene Brana Garcia
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...s/HDAC-inhibitors-and-check-point-inhibitors

Despite successes in the treatment of melanoma patients with checkpoint inhibitors (CI), most patients do not respond to CI alone and a high unmet medical need remains for these patients.

Date: 05 Mar 2018
Presenter: René Bartz
Resources: Abstract, Presentation, Webcast
Topic: Anticancer Agents

https://oncologypro.esmo.org/Meeting-Resour...anced-HER2-Positive-Breast-or-Gastric-Cancer

MEDI4276 is a HER2-bispecific antibody targeting two different epitopes on HER2, with site-specific conjugation via maleimidocaproyl linker to a potent tubulysin-based microtubule inhibitor.

Date: 05 Mar 2018
Presenter: Mark Pegram
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Gastric Cancer, Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...fractory-R-R-B-cell-Non-Hodgkin-Lymphoma-NHL

Patients (pts) with NHL experiencing early relapse (ER) within two years of initial diagnosis and those double refractory (DR) to both rituximab and chemotherapy have particularly poor outcomes (Casulo et al JCO 2015; Gopal et al.

Date: 05 Mar 2018
Presenter: Jean-Marie Michot
Resources: Abstract, Presentation, Webcast
Topics: Lymphomas, Immunotherapy, Haematological Malignancies

https://oncologypro.esmo.org/Meeting-Resour...ents-and-causes-resistance-to-RAF-inhibitors

The mutation in BRAF kinase at V600 has been frequently reported in nearly 50% of melanoma patients resulting in the hyper-activation of MAPK pathway. As such, various inhibitors which target mutant...

Date: 05 Mar 2018
Presenter: Azad Saei
Resources: Abstract
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...3965-in-patients-with-advanced-solid-tumours

A key metabolic alteration in tumour cells is increased dependency on glycolysis, resulting in the production of lactate which is transported out of cells by MCTs.

Date: 05 Mar 2018
Presenter: Ruth Plummer
Resources: Abstract, Presentation, Webcast
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...ith-special-focus-on-haematological-diseases

Date: 05 Mar 2018
Presenter: Tak Mak

https://oncologypro.esmo.org/Meeting-Resour...-Therapies/Genomic-guided-trials-in-lymphoma

Date: 05 Mar 2018
Presenter: Anas Younes

https://oncologypro.esmo.org/Meeting-Resour...abolism-drug-development-in-myeloid-diseases

Mutations in isocitrate dehydrogenase (IDH)1 or IDH2 are seen in ~15–20% of patients with acute myeloid leukemia (AML). Mutant IDH (mIDH) reduces α-ketoglutarate to the oncometabolite 2-hydroxyglutarate ...

Date: 05 Mar 2018
Presenter: David Schenkein
Resources: Abstract, Presentation, Webcast